ATR - AptarGroup, Inc.
110.95 +0.25 (0.23%)
After hours: 4:26PM EST
| Previous Close | 110.50 |
| Open | 110.12 |
| Bid | 110.76 x 800 |
| Ask | 110.79 x 800 |
| Day's Range | 110.38 - 111.85 |
| 52 Week Range | 88.26 - 126.20 |
| Volume | 881,333 |
| Avg. Volume | 226,278 |
| Market Cap | 7.077B |
| Beta (3Y Monthly) | 0.71 |
| PE Ratio (TTM) | 31.15 |
| EPS (TTM) | 3.55 |
| Earnings Date | Feb 18, 2020 - Feb 24, 2020 |
| Forward Dividend & Yield | 1.44 (1.31%) |
| Ex-Dividend Date | 2019-10-29 |
| 1y Target Est | 111.44 |
- Simply Wall St.
Is AptarGroup (NYSE:ATR) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Zacks
New Strong Sell Stocks for November 6th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Thomson Reuters StreetEvents
Edited Transcript of ATR earnings conference call or presentation 1-Nov-19 1:00pm GMT
Q3 2019 Aptargroup Inc Earnings Call
- Zacks
AptarGroup (ATR) Earnings Miss, Revenues Meet Estimates in Q3
AptarGroup (ATR) delivers better-than-anticipated top-line growth in Q3, driven by strong broad-based demand for drug delivery and food dispensing solutions.
- Zacks
AptarGroup (ATR) Lags Q3 Earnings Estimates
AptarGroup (ATR) delivered earnings and revenue surprises of -2.11% and 0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Aptar Reports Third Quarter Results; Acquires Noble International, a Leader in Drug Delivery Training Devices and Patient Onboarding; Announces Segment Leadership Appointments
AptarGroup, Inc. , a global leader in consumer dispensing, active packaging and drug delivery solutions, today reported its third quarter 2019 financial results. In addition, Aptar has acquired Noble International , a leader in drug delivery training devices and patient onboarding and announced certain segment leadership appointments.
- GuruFocus.com
Ken Fisher Continues to Buy PayPal, Caterpillar
Guru’s largest buys of the last 2 quarters Continue reading...
- Zacks
GEF vs. ATR: Which Stock Should Value Investors Buy Now?
GEF vs. ATR: Which Stock Is the Better Value Option?
- Simply Wall St.
Why AptarGroup, Inc.’s (NYSE:ATR) Return On Capital Employed Is Impressive
Today we'll look at AptarGroup, Inc. (NYSE:ATR) and reflect on its potential as an investment. Specifically, we're...
- Zacks
AptarGroup (ATR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AptarGroup (ATR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Aptar Opens New Technical Education Center Focused on Training and Retaining Manufacturing Talent
AptarGroup, Inc. (ATR), a global leader in consumer dispensing, drug delivery and active packaging solutions, hosted a grand opening event for its new Technical Education Center (TEC) in Lincolnton, NC. This facility is part of Aptar’s Corporate Vocational University (CVU) training program and will provide both six and twelve month training opportunities for manufacturing roles. “The availability of technical skilled workers is a precondition to reach operational excellence at Aptar and an internal education program will be a critical advantage for us,” explained Stephan Tanda, Aptar President and CEO.
- Business Wire
Aptar’s Activ-Blister™ Packaging Solution Approved by U.S. FDA for Oral Solid Dose HIV Prevention Medicine
AptarGroup, Inc. , a global leader in consumer dispensing, active packaging and drug delivery solutions, today announced that its Activ-Blister™ packaging solution for oral solid dose drug delivery was recently approved by the U.S.
- Insider Monkey
Hedge Funds Are Warming Up To AptarGroup, Inc. (ATR)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a […]
- PR Newswire
Bryn Pharma Partners with Aptar Pharma for Nasal Epinephrine Treatment
RALEIGH, N.C., Oct. 21, 2019 /PRNewswire/ -- Bryn Pharma, LLC ("Bryn" or the "Company"), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced that it has entered into an agreement with Aptar Pharma (AptarGroup NYSE: ATR), a leading drug delivery systems provider, for the supply and worldwide exclusive right to use Aptar's novel, FDA-approved Bidose (BDS) nasal device for the delivery of epinephrine to treat anaphylaxis.
- Business Wire
Aptar Declares Quarterly Dividend
The Board of Directors of AptarGroup, Inc. (ATR) today declared a quarterly cash dividend of $0.36 per share. The payment date is November 20, 2019, to stockholders of record as of October 30, 2019. As previously announced, Aptar will hold a conference call on Friday, November 1, 2019 at 8:00 a.m. Central Time to discuss the Company’s third quarter results for 2019.
- Zacks
Why AptarGroup (ATR) is Poised to Beat Earnings Estimates Again
AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Aptar Joins Catalyst CEO Champions For Change to Accelerate the Progress and Representation of Women in its Global Workforce
AptarGroup, Inc. (ATR), a global leader in dispensing, sealing and active packaging solutions, announced today that it has joined the Catalyst CEO Champions For Change. With a strong commitment from Aptar’s President and CEO, Stephan Tanda, the company is focused on furthering gender equality, diversity, and inclusion in the workplace. The Catalyst CEO Champions For Change is a transformational diversity and inclusion initiative launched by Catalyst, a global thought leader and partner in accelerating the progress of women at work for over 50 years.
- Zacks
AptarGroup (ATR) to Buy 49% Stake in BTY, Expand in Asia
AptarGroup, Inc. (ATR) has signed an agreement to acquire 49% equity interest in three related BTY companies in China that is in sync with its strategy to grow in Asia.
- Zacks
Reasons Why Investors Should Avoid Berry Global Stock Now
Berry Global (BERY) suffers from forex woes, high debts, rising costs and softness in some segments.
- Simply Wall St.
Are AptarGroup, Inc. (NYSE:ATR) Investors Paying Above The Intrinsic Value?
Does the October share price for AptarGroup, Inc. (NYSE:ATR) reflect what it's really worth? Today, we will estimate...
- Business Wire
Aptar to Acquire a Strategic Equity Interest in BTY, a Leading Chinese Color Cosmetics Packaging Manufacturer
AptarGroup, Inc. (ATR), a global leader in dispensing, drug delivery and active packaging solutions, announced today that it has signed an agreement to acquire a 49% equity interest in three related BTY companies: Suzhou Hsing Kwang (“SZHK”), Suqian Hsing Kwang (“SQHK”) and Suzhou BTY (“BTY”), collectively referred to as BTY. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies and complete color cosmetics packaging solutions for the beauty industry.
- Simply Wall St.
Is AptarGroup, Inc.'s (NYSE:ATR) ROE Of 14% Impressive?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Zacks
AptarGroup (ATR) Rises 24% YTD: What's Driving the Rally?
AptarGroup's (ATR) ongoing business transformation plan, innovative product roll outs and focused on expanding business through acquisitions are likely to help it to grow further.
- PR Newswire
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered vazegepant (formerly BHV-3500) for the acute treatment of migraine. Vazegepant is a novel, structurally unique, third-generation calcitonin gene-related peptide (CGRP) receptor antagonist and the second product candidate in development for the acute treatment of migraine from Biohaven's NOJECTION™ Migraine Platform.
